Updated phase 1b results demonstrate 60% disease control rate, encouraging anti-tumour activity and excellent safety profile for first-in-class therapy.
Medannex Ltd (Edinburgh) today announced the presentation of updated clinical data from Module 1 of the ongoing ATTAINMENT study of MDX-124 at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid.
For full details please click here.